Cannara Financial Statements From 2010 to 2024

LOVE Stock  CAD 0.68  0.01  1.49%   
Cannara Biotech financial statements provide useful quarterly and yearly information to potential Cannara Biotech investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cannara Biotech financial statements helps investors assess Cannara Biotech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cannara Biotech's valuation are summarized below:
Cannara Biotech does not presently have any fundamental signals for analysis.
Check Cannara Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cannara Biotech's main balance sheet or income statement drivers, such as , as well as many indicators such as . Cannara financial statements analysis is a perfect complement when working with Cannara Biotech Valuation or Volatility modules.
  
This module can also supplement various Cannara Biotech Technical models . Check out the analysis of Cannara Biotech Correlation against competitors.

Cannara Biotech Company Return On Asset Analysis

Cannara Biotech's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Return On Asset

 = 

Net Income

Total Assets

More About Return On Asset | All Equity Analysis

Current Cannara Biotech Return On Asset

    
  0.0378  
Most of Cannara Biotech's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cannara Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Competition

Based on the latest financial disclosure, Cannara Biotech has a Return On Asset of 0.0378. This is 100.43% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on asset for all Canada stocks is 127.0% lower than that of the firm.

Cannara Biotech Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Cannara Biotech's current stock value. Our valuation model uses many indicators to compare Cannara Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cannara Biotech competition to find correlations between indicators driving Cannara Biotech's intrinsic value. More Info.
Cannara Biotech is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about  0.56  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Cannara Biotech is roughly  1.79 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cannara Biotech's earnings, one of the primary drivers of an investment's value.

About Cannara Biotech Financial Statements

Cannara Biotech investors use historical fundamental indicators, such as Cannara Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cannara Biotech. Please read more on our technical analysis and fundamental analysis pages.
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-infused products in Canada. The company was incorporated in 2017 and is headquartered in Montreal, Canada. CANNARA BIOTECH is traded on Commodity Exchange in Exotistan.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Cannara Stock Analysis

When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.